[PR Newswire] – DUBLIN and BUDAPEST, Hungary, May 12, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that nine posters highlighting additional scientific data and clinical research … Read more on this. Allergan plc (AGN) , valued at $88.71B, finished yesterday at $222.71. Shares have traded today between $223.27 and $226.25 per share and has traded between $195.50 and $340.34 over the past year. AGN shares are currently priced at 15.75x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 4.50x earnings multiple for the same period. The company pays shareholders $0.20 per share annually in dividends, yielding 0.10%. In a review of the consensus earnings estimate this quarter, 17 sell-side analysts are looking at $3.37 per share, which would be $1.04 worse than the year-ago quarter and a $0.56 sequential decrease. Investors should also note that the full-year EPS estimate of $14.14 is a $0.71 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $4.11 Billion. If realized, that would be a 28.27% decrease over the year-ago quarter. In terms of ratings, Guggenheim Initiated AGN at Neutral (Apr 18, 2016). Previously, Piper Jaffray downgraded AGN from Overweight to Neutral. When considering if perhaps the stock is under or overvalued, the average price target is $293.75, which is 31.90% above where the stock opened this morning. See more in (NYSE:AGN) Similar Articles: Market Update (NYSE:AGN): Allergan Announces U.S. Availability of VRAYLAR™ (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults Company Update: Allergan Inc (NYSE:AGN) – Allergan Presents Data at the 2016 American Academy of Dermatology (AAD) Annual Meeting in Washington D.C. Stock Update: Allergan Inc (NYSE:AGN) – Allergan and Pfizer to Present at 34th Annual J.P. Morgan Healthcare Conference